Stuart C Gordon

Summary

Affiliation: Henry Ford Hospital
Country: USA

Publications

  1. doi request reprint Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET
    Stuart C Gordon
    Department of Internal Medicine, Division of Gastroenterology Hepatology, Henry Ford Hospital, Detroit, MI, USA Electronic address
    J Hepatol 62:286-93. 2015
  2. doi request reprint Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population
    Stuart C Gordon
    Henry Ford Health System, Detroit, Michigan Electronic address
    Clin Gastroenterol Hepatol 12:885-93. 2014
  3. doi request reprint Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease
    S C Gordon
    Henry Ford Health System, Detroit, MI, USA
    Aliment Pharmacol Ther 38:784-93. 2013
  4. doi request reprint Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin
    S C Gordon
    Henry Ford Hospital, Detroit, MI 48202 2689, USA
    Aliment Pharmacol Ther 38:16-27. 2013
  5. doi request reprint Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection
    Stuart C Gordon
    Henry Ford Health System, Detroit, MI, USA
    Hepatology 56:1651-60. 2012
  6. doi request reprint Risk for renal cell carcinoma in chronic hepatitis C infection
    Stuart C Gordon
    Division of Gastroenterology and Hepatology, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48202, USA
    Cancer Epidemiol Biomarkers Prev 19:1066-73. 2010
  7. doi request reprint Acute hepatitis B in an urban tertiary care hospital in the United States: a cohort evaluation
    Omar Sharif
    Department of Gastroenterology K 7, Division of Gastroenterology and Hepatology, Henry Ford Health Medical Center, Detroit, MI
    J Clin Gastroenterol 47:e87-90. 2013
  8. doi request reprint Comparative effectiveness research of chronic hepatitis B and C cohort study (CHeCS): improving data collection and cohort identification
    Mei Lu
    Departments of Public Health Sciences, Center for Health Services Research, and Gastroenterology, Henry Ford Health System, One Ford Place, 3E, Detroit, MI, 48202, USA
    Dig Dis Sci 59:3053-61. 2014
  9. doi request reprint Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
    Paul Y Kwo
    Department of Medicine, Division of Gastroenterology Hepatology, Indiana University School of Medicine, Indianapolis, IN 46202 5121, USA
    Lancet 376:705-16. 2010
  10. pmc Predictors of consent to pharmacogenomics testing in the IDEAL study
    Alison B Jazwinski
    aDepartment of Medicine, Division of Gastroenterology and Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina bDepartment of Medicine, Division of Gastroenterology Hepatology, Henry Ford Hospital, Detroit, Michigan cDepartment of Medicine, Alamo Medical Research, San Antonio, Texas dMerck Research Laboratories, Department of Infectious Disease, Whitehouse Station, New Jersey eDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA fDepartment of Gastroenterology, St Vincent s Hospital, University of Melbourne, Melbourne, Victoria, Australia
    Pharmacogenet Genomics 23:619-23. 2013

Collaborators

Detail Information

Publications19

  1. doi request reprint Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET
    Stuart C Gordon
    Department of Internal Medicine, Division of Gastroenterology Hepatology, Henry Ford Hospital, Detroit, MI, USA Electronic address
    J Hepatol 62:286-93. 2015
    ..The safety profiles of boceprevir and telaprevir in the treatment of chronic hepatitis C, administered in academic and community centres across the United States, were evaluated...
  2. doi request reprint Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population
    Stuart C Gordon
    Henry Ford Health System, Detroit, Michigan Electronic address
    Clin Gastroenterol Hepatol 12:885-93. 2014
    ..We evaluated the relationship between therapy for chronic HBV infection and HCC incidence using data from a longitudinal study of patients at 4 US healthcare centers...
  3. doi request reprint Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease
    S C Gordon
    Henry Ford Health System, Detroit, MI, USA
    Aliment Pharmacol Ther 38:784-93. 2013
    ..The effect of anti-viral treatment on downstream costs for hepatitis C virus (HCV)-infected patients is unknown...
  4. doi request reprint Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin
    S C Gordon
    Henry Ford Hospital, Detroit, MI 48202 2689, USA
    Aliment Pharmacol Ther 38:16-27. 2013
    ..Adherence to therapeutic regimens affects the efficacy of peginterferon alfa (P) and ribavirin (R) therapy in patients with chronic hepatitis C virus genotype 1...
  5. doi request reprint Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection
    Stuart C Gordon
    Henry Ford Health System, Detroit, MI, USA
    Hepatology 56:1651-60. 2012
    ..Overall, 56% of costs were HCV-related and this proportion increased with severity (46%, 57%, and 71% for patients with NCD, CC, and ESLD, respectively)...
  6. doi request reprint Risk for renal cell carcinoma in chronic hepatitis C infection
    Stuart C Gordon
    Division of Gastroenterology and Hepatology, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48202, USA
    Cancer Epidemiol Biomarkers Prev 19:1066-73. 2010
    ..We sought to determine whether HCV infection confers an increased risk for developing RCC...
  7. doi request reprint Acute hepatitis B in an urban tertiary care hospital in the United States: a cohort evaluation
    Omar Sharif
    Department of Gastroenterology K 7, Division of Gastroenterology and Hepatology, Henry Ford Health Medical Center, Detroit, MI
    J Clin Gastroenterol 47:e87-90. 2013
    ..The incidence of acute hepatitis B virus (HBV) infection in the United States is declining, and precise epidemiology for newly acquired infection remains obscure...
  8. doi request reprint Comparative effectiveness research of chronic hepatitis B and C cohort study (CHeCS): improving data collection and cohort identification
    Mei Lu
    Departments of Public Health Sciences, Center for Health Services Research, and Gastroenterology, Henry Ford Health System, One Ford Place, 3E, Detroit, MI, 48202, USA
    Dig Dis Sci 59:3053-61. 2014
    ..We hypothesized that comparative effectiveness methods-including a centralized data management system and an adaptive approach for cohort selection-would improve cohort selection while controlling data quality and reducing the cost...
  9. doi request reprint Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
    Paul Y Kwo
    Department of Medicine, Division of Gastroenterology Hepatology, Indiana University School of Medicine, Indianapolis, IN 46202 5121, USA
    Lancet 376:705-16. 2010
    ..We tested the efficacy of boceprevir, an NS3 hepatitis C virus oral protease inhibitor, when added to peginterferon alfa-2b and ribavirin...
  10. pmc Predictors of consent to pharmacogenomics testing in the IDEAL study
    Alison B Jazwinski
    aDepartment of Medicine, Division of Gastroenterology and Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina bDepartment of Medicine, Division of Gastroenterology Hepatology, Henry Ford Hospital, Detroit, Michigan cDepartment of Medicine, Alamo Medical Research, San Antonio, Texas dMerck Research Laboratories, Department of Infectious Disease, Whitehouse Station, New Jersey eDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA fDepartment of Gastroenterology, St Vincent s Hospital, University of Melbourne, Melbourne, Victoria, Australia
    Pharmacogenet Genomics 23:619-23. 2013
    ..Genome-wide association studies subsequently identified associations between IL28B polymorphism and sustained virologic response, and ITPA polymorphism and ribavirin-associated anemia...
  11. doi request reprint Role of liver biopsy in the era of direct-acting antivirals
    Humberto C Gonzalez
    Henry Ford Health System, 2799 W Grand Boulevard, Detroit, MI, 48202, USA
    Curr Gastroenterol Rep 15:307. 2013
    ..Indirect laboratory formulas, tests, panels of biomarkers and imaging modalities may accurately stage the degree of fibrosis in hepatitis C monoinfection, hepatitis C/HIV coinfection, and post-transplant recurrent hepatitis C...
  12. pmc Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load
    Stuart C Gordon
    Henry Ford Health System, Detroit, MI, USA
    Hepatology 58:505-13. 2013
    ..No patient with baseline HVL had persistent viremia at week 240 or amino acid substitutions associated with TDF resistance...
  13. doi request reprint Evaluation of anti-HBV drug resistant mutations among patients with acute symptomatic hepatitis B in the United States
    Dwayne M Baxa
    Infectious Disease, Henry Ford Hospital, Detroit, MI, USA
    J Hepatol 58:212-6. 2013
    ..Whether resistant HBV strains are transmitted in the acute setting is uncertain. We sought to document the presence of antiviral resistance (AVR) mutations in patients with acute HBV (AHB) infection...
  14. doi request reprint Care of the cirrhotic patient
    Syed Mohammed Jafri
    Gastroenterology Hepatology, Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI 48202, USA
    Infect Dis Clin North Am 26:979-94. 2012
    ..The infectious disease specialist is now becoming familiarized with the management of viral hepatitis, which includes screening for hepatocellular carcinoma and vigilance for infectious complications of antiviral therapy...
  15. doi request reprint Post-Transplant Course of Hepatitis C After Living Donor Liver Transplantation in Association with Polymorphisms near IFNL3
    Kristin G Monaghan
    1 Medical Genetics, Henry Ford Health System, Detroit, Michigan
    J Interferon Cytokine Res 35:313-6. 2015
    ..Recipients with the favorable rs12979860 genotype receiving antiviral therapy before transplant are also more likely to achieve SVR. The effect of genotype status in the era of direct-acting antiviral agents will require future study. ..
  16. doi request reprint Is previous exposure to hepatitis B a risk factor for pancreatic cancer or hepatocellular carcinoma?
    Jeffrey Tang
    Department of Internal Medicine, Division of Gastroenterology Hepatology Department of Biostatistics and Research Epidemiology, Henry Ford Hospital, Detroit, MI
    J Clin Gastroenterol 48:729-33. 2014
    ..We evaluated whether prior infection with the hepatitis B virus (HBV) influences the development of pancreatic cancer or hepatocellular carcinoma (HCC)...
  17. doi request reprint Adefovir dipivoxil in chronic hepatitis B: history and current uses
    Maria C Segovia
    Division of Gastroenterology and Hepatology, Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI 48202, USA
    Expert Opin Pharmacother 13:245-54. 2012
    ..ADV 10 mg daily has been associated with improved liver histology, decreased levels of HBV DNA and alanine aminotransferase (ALT), and seroconversion of HBeAg...
  18. doi request reprint Boceprevir plus peginterferon α-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response
    Stuart C Gordon
    Division of Gastroenterology Hepatology, Henry Ford Hospital, Detroit, MI Division of Gastroenterology Hepatology, University of Pennsylvania, Philadelphia, PA Weill Cornell Medical College, New York, NY University of Texas Health Science Center, San Antonio, TX INSERM U954, Centre Hospitalier Universitaire de Nancy, Université de Lorraine, Vandoeuvre les Nancy, France Saint Louis University School of Medicine, St Louis, MO Hospital General Universitari Vall d Hebrón and Ciberehd del Instituto Carlos III, Barcelona, Spain Division of Gastroenterology and Hepatology, University of California Irvine, Orange, CA Merck Sharp and Dohme Corp, Whitehouse Station, NJ
    J Clin Gastroenterol 48:435-43. 2014
    ..The impact of baseline viral load on sustained virologic response (SVR) after boceprevir-based therapy is unknown...
  19. ncbi request reprint Bioelectrical impedance analysis for the evaluation of hepatic fibrosis in patients with chronic hepatitis C infection
    Fadi Antaki
    Division of Gastroenterology, John D Dingell VA Medical Center, 4646 John R Road, Detroit, MI 48201, USA
    Dig Dis Sci 53:1957-60. 2008
    ..9) in the minimal and advanced fibrosis groups, respectively. Bioelectrical impedance analysis did not demonstrate the ability to distinguish between minimal and advanced degrees of hepatic fibrosis in patients with chronic HCV infection...